BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9816314)

  • 1. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden.
    Mouawad R; Benhammouda A; Rixe O; Antoine EC; Borel C; Weil M; Khayat D; Soubrane C
    Clin Cancer Res; 1996 Aug; 2(8):1405-9. PubMed ID: 9816314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients.
    Mouawad R; Soubrane C; Rixe O; Khayat D; Spano JP
    Melanoma Res; 2006 Aug; 16(4):335-40. PubMed ID: 16845329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study.
    Mouawad R; Rixe O; Meric JB; Khayat D; Soubrane C
    Cytokines Cell Mol Ther; 2002; 7(4):151-6. PubMed ID: 14660055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.
    Zhang GJ; Adachi I
    Anticancer Res; 1999; 19(2B):1427-32. PubMed ID: 10365118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Measurement of five cytokines in the serum of malignant lymphoma patients].
    Zhu H; Wang Y; Han X
    Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):85-8. PubMed ID: 10921109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma.
    Boyano MD; Garcia-Vázquez MD; López-Michelena T; Gardeazabal J; Bilbao J; Cañavate ML; Galdeano AG; Izu R; Díaz-Ramón L; Raton JA; Díaz-Pérez JL
    Br J Cancer; 2000 Oct; 83(7):847-52. PubMed ID: 10970683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma.
    Guida M; Riccobon A; Biasco G; Ravaioli A; Casamassima A; Freschi A; Palma MD; Galligioni E; Nortilli R; Chiarion-Sileni V; Picozzo J; Romanini A; Nanni O; Ridolfi R;
    Melanoma Res; 2006 Aug; 16(4):317-23. PubMed ID: 16845327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome.
    Mouawad R; Spano JP; Comperat E; Capron F; Khayat D
    Eur J Cancer; 2009 May; 45(8):1407-14. PubMed ID: 19157860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy.
    Cheon YK; Cho YD; Moon JH; Jang JY; Kim YS; Kim YS; Lee MS; Lee JS; Shim CS
    Am J Gastroenterol; 2007 Oct; 102(10):2164-70. PubMed ID: 17617204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum interleukin-8 level is a more sensitive marker than serum interleukin-6 level in monitoring the disease activity of recurrent aphthous ulcerations.
    Sun A; Chang YF; Chia JS; Chiang CP
    J Oral Pathol Med; 2004 Mar; 33(3):133-9. PubMed ID: 15128054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer.
    Rich T; Innominato PF; Boerner J; Mormont MC; Iacobelli S; Baron B; Jasmin C; Lévi F
    Clin Cancer Res; 2005 Mar; 11(5):1757-64. PubMed ID: 15755997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma.
    Hsia CY; Huo TI; Chiang SY; Lu MF; Sun CL; Wu JC; Lee PC; Chi CW; Lui WY; Lee SD
    Eur J Surg Oncol; 2007 Mar; 33(2):208-12. PubMed ID: 17140760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum interleukin-8 level is a more sensitive marker than serum interleukin-6 level in monitoring the disease activity of oral lichen planus.
    Sun A; Wang JT; Chia JS; Chiang CP
    Br J Dermatol; 2005 Jun; 152(6):1187-92. PubMed ID: 15948980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
    Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
    Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma.
    Deichmann M; Benner A; Waldmann V; Bock M; Jäckel A; Näher H
    J Exp Clin Cancer Res; 2000 Sep; 19(3):301-7. PubMed ID: 11144523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse.
    Reinisch W; Gasché C; Tillinger W; Wyatt J; Lichtenberger C; Willheim M; Dejaco C; Waldhör T; Bakos S; Vogelsang H; Gangl A; Lochs H
    Am J Gastroenterol; 1999 Aug; 94(8):2156-64. PubMed ID: 10445543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in cytokine levels in melanoma patients with and without redness (Brenner sign).
    Mashiah J; Brenner S; Pessach Y; Barak V; Schachter J
    Anticancer Res; 2009 May; 29(5):1793-6. PubMed ID: 19443406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease.
    Chen DY; Lan JL; Lin FJ; Hsieh TY
    J Rheumatol; 2004 Nov; 31(11):2189-98. PubMed ID: 15517632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.